Phaseline

Companies › Friendi.fi

Friendi.fi: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Neurology; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Digital STEADI-1
Tablet-based avatar delivering STEADI fall risk screening, monitoring and exercise program
–Phase 1FallMay 2028
Digital STEADI-2
SMS chat-based delivery of STEADI fall risk screening, monitoring and exercise program
–Phase 1FallMay 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07852650Digital STEADI-1Phase 1FallNeurologyMay 2028
NCT07852650Digital STEADI-2Phase 1FallNeurologyMay 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.